Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention | Journal of the American College of Cardiology
Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial | DAIC
Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI | tctmd.com
CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events | tctmd.com
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
تويتر \ Davide Capodanno على تويتر: "@A_N_Mahmoud_MD PLATFORM is versus placebo and PHOENIX is versus an active control. A key reason however is a variation in the definition of periprocedural MI, using
Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction - ScienceDirect
Platelet Inhibition with Cangrelor in Patients Undergoing PCI | NEJM
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Intravenous Platelet Blockade with Cangrelor during PCI | NEJM
Consistent Reduction in MI with Cangrelor Deepak L - ppt download
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data - The Lancet
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION | Circulation: Cardiovascular Interventions
48 hour efficacy of cangrelor observed in the CHAMPION Trials | Download Scientific Diagram
RX List database - use generic or medication brand name - GlobalRPH
Efficacy and Safety | KENGREAL® (cangrelor)
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX | Circulation: Cardiovascular Interventions
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
CRT 2021: Analysis compares cangrelor favourably to glycoprotein IIB - Cardiovascular News
Cangrelor succeeds, at last, in PCI | Nature Reviews Cardiology
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
Cangrelor for treatment during percutaneous coronary intervention | Future Cardiology
Practical considerations for cangrelor use in patients with acute coronary syndromes - Sergio Leonardi, Deepak L Bhatt, 2019
JCM | Free Full-Text | Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
